报价延迟最少15分钟:2025/11/16 11:05 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.29 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.13/-2.48
|
|
企业价值
179.75M
|
| 资产负债 |
|
每股账面净值
-0.92
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.00M
|
|
每股收益
0.16
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 11:05 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. |
